Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505736 · ClinicalTrials.gov registry record
Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 25
- Enrollment target
NCT03505736: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03505736 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03505736 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatments including chemotherapy and aromatase inhibitors.
Primary Outcome
Will first estimate 95% confidence intervals for each group at each time point as well as for the change from baseline to 3-6-months in each group.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Regadenoson
- PROCEDURE Stress Management Therapy
- BIOLOGICAL Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2020-03-05 |
What the finished NCT03505736 record still lists
NCT03505736 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03505736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03505736 about?
NCT03505736 is a clinical study titled "Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer". This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatme...
What is the current status of trial NCT03505736?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-06-21. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03505736?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Regadenoson (DRUG), Stress Management Therapy (PROCEDURE), Adenosine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03505736?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI